IDEXX Laboratories Inc.

03/03/2026 | Press release | Distributed by Public on 03/03/2026 20:45

Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Erickson Michael G
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Executive Vice President
(Last) (First) (Middle)
ONE IDEXX DRIVE
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
(Street)
WESTBROOK, ME 04092
4. If Amendment, Date Original Filed (Month/Day/Year)
02/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 15,092.351(1) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)(2) $617.2 02/12/2026 A 13,667 (3) 02/11/2036 Common Stock 13,667 $ 0 13,667 D
Incentive Stock Option (right-to-buy)(2) $617.2 02/12/2026 A 162 (4) 02/11/2036 Common Stock 162 $ 0 162 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Erickson Michael G
ONE IDEXX DRIVE
WESTBROOK, ME 04092
Executive Vice President

Signatures

/s/ Lily J. Lu, Attorney-in-Fact for Michael G. Erickson 03/03/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes 184 vested but deferred restricted stock units.
(2) This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4.
(3) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
(4) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
IDEXX Laboratories Inc. published this content on March 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 04, 2026 at 02:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]